echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Hengrui Medicine's 5 anti-tumor studies are selected for Oral link

    Hengrui Medicine's 5 anti-tumor studies are selected for Oral link

    • Last Update: 2021-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Pharmaceutical Guanlan

    Recently, the official website of the American Society of Clinical Oncology (ASCO) annual meeting officially announced the abstract of the 2021 ASCO conference.


    1.


    1.


    Mechanism of action: anti-PD-1 monoclonal antibody

    Research information: A randomized, double-blind, placebo-controlled Phase 3 clinical study (ESCORT-1st) to evaluate carrelizumab combined with chemotherapy versus chemotherapy for untreated advanced or metastatic esophageal squamous cells Effect for cancer patients

    Research information: A randomized, double-blind, placebo-controlled Phase 3 clinical study (ESCORT-1st) to evaluate carrelizumab combined with chemotherapy versus chemotherapy for untreated advanced or metastatic esophageal squamous cells Effect for cancer patients

    Research leader: Professor Xu Ruihua, Sun Yat-sen University Cancer Center

    Research leader: Professor Xu Ruihua, Sun Yat-sen University Cancer Center

    From December 3, 2018 to May 12, 2020, 596 patients received randomization.


    In the study, the incidence of ≥ grade 3 treatment-related adverse reactions in the two groups was similar (63.


    2.


    2.


    Mechanism of action: anti-PD-1 monoclonal antibody

    Research information: A randomized controlled, double-blind, multi-center phase 3 clinical trial (CAPTAIN-1st) to evaluate the effect of carrelizumab combined with gemcitabine and cisplatin in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma

    Research information: A randomized controlled, double-blind, multi-center phase 3 clinical trial (CAPTAIN-1st) to evaluate the effect of carrelizumab combined with gemcitabine and cisplatin in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma

    Research leader: Professor Zhang Li, Sun Yat-sen University Cancer Center

    Research leader: Professor Zhang Li, Sun Yat-sen University Cancer Center

    From November 2018 to November 2019, 263 patients from 28 centers were randomly assigned to carrelizumab + GP (gemcitabine + cisplatin) group (n=134, carrelizumab group) ) Or placebo+GP group (n=129, placebo group).


    In terms of side effects, the incidence of ≥3 treatment-related adverse events (TRAEs) was 93% in the carrelizumab group and 90% in the placebo group.


    3.


    3.


    Mechanism of action: CDK4/6 inhibitor

    Research information: A multi-center, randomized, phase 3 study (DAWNA-1) to evaluate the effect of dapicilil versus placebo plus fulvestrant in the treatment of HR+/HER2-advanced breast cancer that has relapsed or progressed from previous endocrine therapy

    Research information: A multi-center, randomized, phase 3 study (DAWNA-1) to evaluate the effect of dapicilil versus placebo plus fulvestrant in the treatment of HR+/HER2-advanced breast cancer that has relapsed or progressed from previous endocrine therapy

    Research leader: Professor Xu Binghe, Cancer Hospital of Chinese Academy of Medical Sciences, National Cancer Center

    Research leader: Professor Xu Binghe, Cancer Hospital of Chinese Academy of Medical Sciences, National Cancer Center

    361 patients were randomized to receive dapiciride + fulvestrant (n=241, dapiciride group) or placebo + fulvestrant (n=120, placebo group) treatment.


    The most common grade 3 or 4 AEs in the dapicillide group were neutropenia (84.


    Four, famitinib + carrelizumab

    Four, famitinib + carrelizumab

    Mechanism of action: multi-target tyrosine kinase inhibitor, anti-PD-1 monoclonal antibody

    Mechanism of action: multi-target tyrosine kinase inhibitor, anti-PD-1 monoclonal antibody

    Research information: A prospective, one-arm, phase 2 study (FUTURE-C-plus) to evaluate famitinib combined with carrelizumab + albumin paclitaxel in the first-line treatment of immunomodulated advanced triple-negative breast cancer Effect

    Research information: A prospective, one-arm, phase 2 study (FUTURE-C-plus) to evaluate famitinib combined with carrelizumab + albumin paclitaxel in the first-line treatment of immunomodulated advanced triple-negative breast cancer Effect

    Research leader: Professor Shao Zhimin, Fudan University Affiliated Cancer Hospital

    Research leader: Professor Shao Zhimin, Fudan University Affiliated Cancer Hospital

    From October 2019 to October 2020, a total of 48 patients were enrolled.


    Grade 3 or 4 adverse events were neutropenia, anemia, febrile neutropenia, thrombocytopenia, hypertension, hypothyroidism, proteinuria, sepsis, and immune-related myocarditis.


    Five, SHR-1701

    Five, SHR-1701

    Mechanism of action: PD-L1/TGF-β double antibody

    Mechanism of action: PD-L1/TGF-β double antibody

    Research information: A phase 1 study exploring the treatment of SHR-1701 in patients with advanced solid tumors

    Research information: A phase 1 study exploring the treatment of SHR-1701 in patients with advanced solid tumors

    Research leader: Professor Lin Shen, Peking University Cancer Hospital

    Research leader: Professor Lin Shen, Peking University Cancer Hospital

    Seventeen cases were included in the dose-climbing stage.


    PK analysis showed that SHR-1701 has a linear relationship with dose exposure in the dose range of 1-30mg/kg.
    Peripheral blood PD-L1 occupancy rate exceeded 90% in all dose groups, and TGF-β1 capture was almost detected in all dose groups.
    Of 49 patients, 45 patients completed at least one efficacy evaluation.
    The ORR was 17.
    8%, and 8 patients achieved partial remission (PR).
    The disease control rate (DCR) is 40.
    0%.
    Most PR patients are still responding (7/8), and the median DoR has not yet been reached.
    Based on safety, PK, PD, and efficacy data, the study recommends 30mg/kg Q3W (use once every 3 weeks) as the recommended dose (RP2D) for the Phase 2 study.

    Reference materials:

    Reference materials:

    [1] Hengrui's original research shines on the world stage, and a number of blockbuster studies are shortlisted for the Oral session of the ASCO annual meeting.
    Retrieved May 25, 2021, from https://mp.
    weixin.
    qq.
    com/s/p-UTs_D6RtGUt5a4b5V7GQ

    [1] Hengrui's original research shines on the world stage, and a number of blockbuster studies are shortlisted for the Oral session of the ASCO annual meeting.
    Retrieved May 25, 2021, from https://mp.
    weixin.
    qq.
    com/s/p-UTs_D6RtGUt5a4b5V7GQ

    ▽ attention [drug Mingkang Germany ] micro-channel public number

    [Medical attention Mingkang Germany ] ] micro-channel public number

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.